XTalks

AUGUST 17, 2020

Cue Biopharma is a Cambridge, Massachusetts-based clinical-stage biotechnology company that is focused on developing injectable immune biologics using its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform. Cell-Based Immunotherapy vs. Immune Biologics. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

FEBRUARY 18, 2021

Researchers from the University of Texas Medical Branch based their findings on lab tests using SARS-CoV-2 coronaviruses that were genetically engineered to have the same mutations as those in the strain that is causing scientists so much concern.

Immune Response 52

Immune Response Genetic Engineering Vaccine Vaccination 52

XTalks

NOVEMBER 23, 2020

Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials. The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions.

Vaccine 97

Vaccine Vaccination Clinical Trials Clinical Trials 97

pharmaphorum

MARCH 10, 2021

The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise a genetically engineered version of SARS-CoV-2 with the P.1 1 – that is worrying health officials around the world. . 1 mutations, as well as variants from the UK and South Africa.

Vaccine 66

Vaccine Vaccination Genetic Engineering Engineer 66

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. About Novavax. Novavax, Inc.?(Nasdaq: Novavax Forward Looking Statements.

Protein 52

Protein Vaccine Vaccination Immune Response 52

pharmaphorum

OCTOBER 12, 2022

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. Inactive viruses often act as the viral vector, as they’re able to deliver genetic therapies efficiently.

Genome 105

Genome Genomics Medicine Development 105

XTalks

NOVEMBER 30, 2023

This candidate, derived from a person’s own genetically modified cells, aims to restore the Gag-specific CD4+ T cell response in those receiving antiretroviral therapy. In November 2023, Hookipa Pharma Inc., Notably, it significantly reduced viral load and clinical illness compared to a placebo. In addition, Vir Biotechnology, Inc.

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

Scienmag

MARCH 1, 2021

Credit: Earlham Institute Respiratory viruses such as SARS-CoV-2 (causing COVID-19) can often catalyse an overactive immune response that leads to a life-threatening cycle, known as a cytokine storm.

Immune Response 59

Immune Response Bioinformatics Allergies Genetics 59

Cloudbyz

MARCH 5, 2024

They are often used to mimic or enhance natural biological processes, such as immune responses. Immunogenicity : Small Molecules: Generally have a lower risk of inducing an immune response in the body. Biologics: Biologics can work in a variety of ways, including targeting specific cells, proteins, or pathways.

Development 97

Development Drugs Immune Response Manufacturing 97

XTalks

MAY 7, 2021

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first, “original” strain of SARS-CoV-2.

Protein 97

Protein Vaccine Vaccination Trials 97

pharmaphorum

APRIL 26, 2022

Research into the area is being made possible through advancements in technology, such as being able to sequence genes at scale, allowing researchers to gain more detailed genetic data on the microbiome. Compelling advantages.

Containment 115

Containment Development Production Drugs 115

The Pharma Data

APRIL 8, 2021

Early clinical results are consistent with preclinical studies and suggest THOR-707 (SAR444245) may promote an anti-tumor immune response without alpha-mediated side effects, both alone and in combination with anti-PD-1. Kenilworth, NJ, USA (known as MSD outside the U.S. About THOR-707 (SAR444245).

Immune Response 52

Immune Response Engineer Antibody Genetics 52

The Pharma Data

JANUARY 17, 2021

These models are engrafted with mouse tumors derived from the same strain background; this genetic similarity between tumor and host prevents the host from rejecting the tumor. One consideration in using syngeneic models is that some drug candidates can cause a negative immune response not seen in humans.

Genetic Engineering 40

Genetic Engineering Genetics Engineer Immune Response 40

The Pharma Data

NOVEMBER 9, 2020

NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.?Novavax?is

Vaccine 52

Vaccine Vaccination Clinical Trials Clinical Trials 52

pharmaphorum

SEPTEMBER 4, 2020

The treatments are developed using cutting- edge technologies such as genomic sequencing and genetic engineering, helping to account for the individual variability in both patient and disease characteristics. These vary in their effectiveness and result in damage to healthy tissues. visible to the patient) and back-end (i.e.

Medicine 59

Medicine Production Genetic Engineering Genetics 59

Advarra

JANUARY 11, 2024

As researchers continue to identify better cellular targets and expand and improve upon immunotherapy approaches, they become better able to predict patient response and better able to learn from cancer cells’ attack strategies. Monoclonal Antibodies Monoclonal antibodies are lab-engineered immune system proteins.

Vaccine 52

Vaccine Vaccination Protein Antibody 52

Roots Analysis

AUGUST 23, 2024

Vaccinations in the past have always been either weak or inactive forms of a pathogen which was given to the body so that our immune system is trained to recognize that given pathogen. In theory we could do this for any infectious disease where we know enough about what molecules provoke an effective immune response.

Protein 40

Protein Vaccine Vaccination Immune Response 40

The Pharma Data

NOVEMBER 30, 2020

CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix?M. About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease.

Clinical Development 52

Clinical Development Vaccine Vaccination Development 52

The Pharma Data

JUNE 1, 2022

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. Previous research has shown that caspase 11 in mice has many of the same immune-response functions as caspase 4 in humans.

Immune Response 52

Immune Response Genetic Engineering Research Engineer 52

Roots Analysis

MAY 21, 2024

LNPs comprise of a lipid bilayer that surrounds a hydrophobic core, which can be loaded with therapeutic agents ( such as drugs, genetic material and proteins ). LNPs can also be engineered to encapsulate multiple antigens, enabling the development of multivalent vaccines.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Cloudbyz

JULY 31, 2024

These technologies provide insights into genetic, proteomic, and metabolomic profiles, enabling the discovery of biomarkers associated with diseases like cancer, cardiovascular diseases, and neurological disorders. For instance, in oncology, patients with specific genetic mutations (e.g.,

Gene Therapy 52

Gene Therapy Gene Medicine In-Vitro 52

The Pharma Data

APRIL 22, 2023

However, many of those therapies cause severe side effects in different parts of the body, including the immune system itself, and thus carry significant health risks. Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard John A.

Immune Response 40

Immune Response Engineer In-Vivo Containment 40

pharmaphorum

NOVEMBER 2, 2021

The more targeted, bispecific functionality of bsAbs broadens the reach of antibody-mediated therapies against both solid and haematological cancers, creating novel approaches that can induce a tumour-specific immune response, target immune checkpoints, or improve payload delivery to tumour cells (Fig.

Antibody 52

Antibody Immune Response Production Engineer 52

The Pharma Data

JUNE 25, 2021

“These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus. NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease.

Vaccine 40

Vaccine Vaccination Trials Immune Response 40

The Pharma Data

OCTOBER 27, 2020

AavantiBio’s strategic partnership with University of Florida’s Powell Gene Therapy Center provide their foundational research in rare genetic disorders. The company’s lead program is aimed at Friedrich’s Ataxia, a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. The company’s $27.4

Gene 52

Gene Gene Therapy Medicine Development 52

Roots Analysis

DECEMBER 11, 2022

Advances in molecular research and genetic manipulation techniques have led to the development of several platforms that can be used to harness the underlying potentials of T-cells and direct their functionality to offer therapeutic benefit. Post amplification engineered T-cells are washed and concentrated.

Marketing 40

Marketing Production Genetics Immune Response 40

WCG Clinical

MAY 28, 2024

CAR-T Cells Target Harmful B Cells in Lupus CAR-T cell technology, which uses genetic engineering to direct white blood cells to attack specific molecular targets, was originally proposed for treatment of HIV infection and hematological malignancies.

In-Vivo 40

In-Vivo Clinical Trials Clinical Trials FDA Approval 40

The Pharma Data

DECEMBER 27, 2020

GM2 gangliosidosis is a rare and fatal monogenic lysosomal storage disorder and a family of neurodegenerative genetic diseases that includes Tay-Sachs and Sandhoff diseases. It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory diseases. Most Read Today.

Trials 52

Trials Antibody Gene Therapy Gene 52

The Pharma Data

JULY 6, 2021

Hemophilia is a rare, genetic bleeding disorder in which a person’s blood does not clot properly. It is engineered by fusing factor VIII to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Eloctate to use a naturally occurring pathway to extend the time the therapy remains in the body.

Protein 52

Protein RNA Development Marketing 52

Roots Analysis

OCTOBER 30, 2023

Self-amplifying RNA (saRNA): Self amplifying RNA is an engineered form of RNA, combining the amplifying genome (native to certain viruses) to the therapeutic gene of interest. The primary target indications for tRNA therapeutics include genetic and oncological disorders.

RNA 40

RNA Vaccine Vaccination Development 40

The Pharma Data

SEPTEMBER 15, 2020

With the depth and breadth of our current portfolio, the tremendous potential of our pipeline and scientific engine, and the power of our culture of innovation, we are poised to continue delivering meaningful value to patients by addressing some of the world’s most difficult health challenges.”.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

pharmaphorum

NOVEMBER 24, 2020

Catamaran’s proprietary platform – called Tailwind – consists of a novel way to design and engineer improved CAR-NK cells using synthetic biology. Finally, Tailwind includes a non-viral delivery system for engineering the CAR-NK cells based on transposons that make them easier and potentially cheaper to manufacture.

Engineer 52

Engineer Immune Response DNA Genome 52

Pharmaceutical Technology

APRIL 24, 2023

In an email to this news service, João Conde, PhD, professor at NOVA Medical School, Universidade NOVA de Lisboa, said advances like the mRNA vaccines serve as a testament to the breakthroughs made by science over decades of research at the junction of genetics and nanomedicine. These could feature in the next four to five years.

Drug Delivery 147

Drug Delivery Vaccine Vaccination Research 147

XTalks

FEBRUARY 11, 2025

Gene therapy has shown promise in treating cancers that are particularly difficult to manage such as neuroblastoma and Wilms tumor using CAR-T cell therapy, CRISPR-Cas9 gene editing and RNA-based interventions to target genetic drivers of disease.

Gene Therapy 66

Gene Therapy Clinical Trials Clinical Trials Trials 66

pharmaphorum

NOVEMBER 23, 2020

Clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.

Antibody 52

Antibody Immune Response Trials Engineer 52